Drug Delivery

Carrington's DelSite subsidiary reports GelVac formulation suitable for nasal delivery

Published in Healthcare Finance, Tax and Law Weekly, December 20th, 2006

Carrington Laboratories, Inc., (CARN) reported that a presentation entitled "Immunoenhancing Effect of a Novel In Situ Gelling Polygalacturonate, GelSite Polymer" was presented at the 4th International Conference on Vaccines, which met November 16-17, 2006 in Washington, D.C.

The presentation was authored by scientists from DelSite Biotechnologies, Inc., with contributions from scientists from Texas A&M University and the National Cancer Institute (NCI), and showed that the GelVac powder formulation developed for nasal application can also be injected after reconstituted, with enhanced immune response.

Data showed that the GelVac vaccine formulations...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2006-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry